Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The first FDA-approved epi-on corneal cross-linking therapy keeps proving its worth. A long-term extension study found that Epioxa sustained meaningful improvements in corneal shape and vision at 3 years — with zero serious adverse events reported. For keratoconus patients, that's a significant milestone.
Epioxa, the first epithelium-on (epi-on) corneal cross-linking therapy approved in the U.S., continues to demonstrate strong results well beyond its initial treatment window. A long-term phase 3 extension study tracked 38 eyes across 35 patients who received a single treatment — no additional interventions — and followed them for three full years. The results showed sustained corneal improvements, meaningful visual acuity gains, and a clean safety record throughout.
The study found that Epioxa maintained a sustained improvement in maximum corneal curvature from baseline, while a notable share of patients saw clinically meaningful vision gains. Importantly, no serious adverse events, treatment-related adverse events, or treatment discontinuations due to adverse events were reported across the entire follow-up period.
By the Numbers:
Why it matters: Keratoconus is a progressive eye condition that can significantly impair vision, and durable treatment options have historically been limited. Epioxa's 3-year data strengthens the case for epi-on cross-linking as a safe, long-lasting solution — offering patients and clinicians greater confidence in a single-treatment approach.
